Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study

Area of Science:

• Oncology
• Pharmacology
• Bone Biology

Background:

• Bone-targeted treatments, including bisphosphonates (e.g., zoledronic acid) and denosumab, are crucial for managing malignant bone disease.
• These therapies reduce skeletal complications and prevent treatment-induced bone loss.
• They may also interrupt the tumor-bone cell signaling 'vicious cycle' within the bone marrow microenvironment.

Purpose of the Study:

• To review the role of bone-targeted treatments in malignant bone disease.
• To examine the impact of these treatments on skeletal complications and bone destruction.
• To explore the influence of reproductive hormones as a modifying factor in treatment efficacy.

Main Methods:

• Review of current literature on bone-targeted therapies in oncology.
• Analysis of clinical trial data for zoledronic acid, denosumab, and clodronate.
• Evaluation of treatment outcomes in relation to patient menopausal status and endocrine therapy.

Main Results:

• Zoledronic acid improves disease-free and overall survival in early-stage breast cancer, particularly in postmenopausal women and premenopausal women receiving ovarian suppression.
• Other bisphosphonates like clodronate may offer similar benefits.
• Denosumab delays bone metastasis development in castrate-resistant prostate cancer.

Conclusions:

• Adjuvant bone-targeted treatments are strongly supported by current evidence.
• Reproductive hormone status is a critical factor that modifies the effectiveness of these therapies.
• Further consideration of hormonal status is essential for optimizing treatment strategies in bone metastases.